Back to mobile site

Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600

October 7, 2016 7:38 AM EDT Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) announced that its collaborator Genentech, a member of the Roche Group (OTC: RHHBY), will present preliminary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login